Reckitt Bids To Delay Mucinex Competition With Bioequivalance Petition
This article was originally published in The Tan Sheet
Executive Summary
In an attempt to delay private-label competition for Mucinex OTC cough products, Reckitt Benckiser asks FDA to ensure potential generics meet the same bioequivalence across the 12-hour dosing interval as the branded product
You may also be interested in...
FDA Denial Of Mucinex Petition Stops Reckitt's Bid To Delay Generics
FDA stymies Reckitt Benckiser's attempt to delay private label competition for Mucinex OTC cough products by rejecting the firm's request to redefine bioequivalence standards for guaifenesin generics
Perrigo Claims Reckitt's Bid To Block Generic Mucinex Is "Baseless"
Reckitt Benckiser's petition seeking to define specific bioequivalence standards for private-label versions of Mucinex OTC cough products, if followed, would push FDA to violate generic drug law, Perrigo argues
Reckitt Benckiser Looks Overseas To Double Adams’ Revenue
Reckitt Benckiser should meet its goal of doubling Adams Respiratory Therapeutics' revenues by launching the firms' OTC cough and congestion products overseas and introducing new products being developed by Adams in the United States, analysts and Reckitt executives say